IMPROVED PREGNANCY OUTCOME WITH GONADOTROPIN-RELEASING-HORMONE AGONIST (GNRH-A) STIMULATION IS DUE TO THE IMPROVEMENT IN OOCYTE QUANTITY RATHER THAN QUALITY

被引:50
作者
LIU, HC
LAI, YM
DAVIS, O
BERKELEY, AS
GRAF, M
GRIFO, J
COHEN, J
ROSENWAKS, Z
机构
[1] Center for Reproductive Medicine and Infertility, Department of Obstetrics and Gynecology, Cornell University Medical College, New York
[2] Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taipei
关键词
EMBRYO QUALITY; EMBRYO QUANTITY; GONADOTROPIN RELEASING HORMONE AGONIST; IMPLANTATION RATE; MULTIPLE PREGNANCY;
D O I
10.1007/BF01203956
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The impact of gonadotropin releasing hormone agonist (GnRH-a) on the quality and quantity of oocytes harvested in in vitro fertilization-embryo transfer (IVF-ET) patients was studied by comparing the results for patients stimulated with gonadotropin alone and with gonadotropin plus GnRH-a. Adding GnRH-a significantly improved the viable pregnancies per transfer and reduced the spontaneous abortions, which seemed to improve oocyte quality. However, when oocyte quality was evaluated by the fertilization rate and the implantation and delivery rates per embryos transferred, there were no significant difference in the results, indicating that GnRH-a did not improve the oocyte quality. On the other hand, GnRH-a significantly increased the average number of oocytes harvested, fertilized, and transferred, and this increased number of oocytes transferred has been demonstrated to increase pregnancy and multiple-pregnancy rates. Multiple pregnancy with more embryos implanted would significantly reduce the abortion rate. Abortion rates decreased inversely to the number of embryos implanted. Our data strongly suggest that the efficacy of GnRH-a on IVF-ET patients was due more to the quantity increase than the quality of embryos transferred.
引用
收藏
页码:338 / 344
页数:7
相关论文
共 22 条
  • [1] Mar R.P., Vargyas J.M., Saito H., Gibbons W.E., Berger T., Mishell D.R., Clinical applications of techniques used in human in vitro fertilization research, Am J Obstet Gynecol, 146, (1983)
  • [2] Neveu S., Hedon B., Bringer J., Chinchole M.J., Arnal F., Humeau C., Crostol P., Viala J.L., Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization, Fertil Steril, 47, (1987)
  • [3] Meldrum D.R., Wisot A., Hamilton F., Gutlay A.L., Kempton W., Huynh D., Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval, Fertil Steril, 51, (1989)
  • [4] Rutherford A.J., Subak-Sharpe R.J., Dawson K.J., Margara R.A., Franks S., Winston R.M.L., Improvement of in vitro fertilization after treatment with buserelin, an agonist of luteinizing hormone releasing hormone, Br Med J, 296, (1988)
  • [5] Chetkowski R.J., Rode A.R., Burruel V., Nass T.E., The effect of pituitary suppression and the women's age on embryo viability and uterine receptivity, Fertil Steril, 56, (1991)
  • [6] Porter R.N., Smith W., Craft J.L., Abdulwahid N.A., Jacobs H.S., Induction of ovulation for in vitro fertilization with buserelin and gonadotropins, Lancet, 2, (1984)
  • [7] de Ziegler D., Cedars M.I., Randle D., Lu J.K.H., Judd H., Meldrum D.R., Suppression of the ovary using a gonadotropin releasing hormone agonist prior to stimulation for the retrieval, Fertil Steril, 48, (1987)
  • [8] Serafini P., Stone B., Kerin J., Batzofin J., Quinn P., Mar R.P., An alternate approach to controlled ovarian hyperstimulation in “poor responders”: Pretreatment with a gonadotropin releasing hormone analog, Fertil Steril, 49, (1988)
  • [9] Palermo R., Amodeo G., Navot D., Rosenwaks Z., Cittadini E., Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction multiple follicles, Fertil Steril, 49, (1986)
  • [10] Fleming R., Coutts J.R.T., Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression, Fertil Steril, 45, (1986)